Fernanda Christtanini Koyama
Research Subjects
Fernanda Christtanini Koyama has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Carolina de Bustamante Fernandes
3 shared publications- Christopher Lucas Negrete
Oncoclinicas Medicina de Precisão, Oncoclínicas & Co, São Paulo, São Paulo, Brazil
3 shared publications Nathalia Pellegrini Correa
3 shared publications- Rodrigo Dienstmann
Oncology Data Science, Vall d’Hebron Institute of Oncology, Barcelona, Spain
3 shared publications Ana Caroline Zimmer Gelatti
2 shared publications- Anamaria Aranha Camargo
Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo 01308-060, SP, Brazil
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Timely Broad Genomic Profiling Improves Delivery of Matched Therapy in Advanced NSCLC: A Nationwide Real-World Study from Brazil
Background: Broad next-generation sequencing (NGS) is essential to identify actionable genomic alterations (AGA) in advanced non-squamous non-small-cell lung cancer (nsNSCLC), but its clinical benefit depends on timely molecular results to guide first-line treatment. We evaluated the impact of NGS timing on treatment selection and clinical outcomes.Methods: We retrospectively evaluated patients with advanced nsNSCLC who underwent centralized molecular profiling through a nationwide patient support program (Brazil, June 2020-December 2023). Treatment lines were defined according to the ESMO EnLiST framework. The primary endpoint was the proportion of patients with AGA receiving genotype-matched therapy in the first-line setting. Secondary endpoints included diagnostic intervals, time to treatment discontinuation (TTD), overall survival (OS), and treatment allocation by NGS timing.Results: Among 1,510 submitted samples, 1,056 (70%) yielded informative NGS results. Of 318 outcome-evaluable patients, 101 (32%) harbored AGA, of whom 89 (88.1%; 95% CI, 80.4–93.1%) received matched therapy in the first-line setting. Overall, 73% of patients initiated first-line treatment after NGS results became available, which was associated with a higher likelihood of matched therapy (OR 5.86; P<0.001) and longer TTD (6.3 vs 2.6 months; HR 0.59; P<0.001). Among patients with AGA, matched therapy was associated with significantly longer TTD (21.2 vs 3.5 months; HR 0.25; P < 0.001) and OS (45.4 vs 16.3 months; HR 0.44; P = 0.019) than non-targeted systemic therapy.Conclusion: Within a nationwide precision oncology program, matched therapy was delivered to nearly 90% of patients with AGA. Earlier NGS result availability improved delivery of precision oncology, whereas receipt of matched therapy was associated with improved overall survival.
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTimely Broad Genomic Profiling Improves Delivery of Matched Therapy in Advanced NSCLC: A Nationwide Real-World Study from Brazil
Background: Broad next-generation sequencing (NGS) is essential to identify actionable genomic alterations (AGA) in advanced non-squamous non-small-cell lung cancer (nsNSCLC), but its clinical benefit depends on timely molecular results to guide first-line treatment. We evaluated the impact of NGS timing on treatment selection and clinical outcomes.Methods: We retrospectively evaluated patients with advanced nsNSCLC who underwent centralized molecular profiling through a nationwide patient support program (Brazil, June 2020-December 2023). Treatment lines were defined according to the ESMO EnLiST framework. The primary endpoint was the proportion of patients with AGA receiving genotype-matched therapy in the first-line setting. Secondary endpoints included diagnostic intervals, time to treatment discontinuation (TTD), overall survival (OS), and treatment allocation by NGS timing.Results: Among 1,510 submitted samples, 1,056 (70%) yielded informative NGS results. Of 318 outcome-evaluable patients, 101 (32%) harbored AGA, of whom 89 (88.1%; 95% CI, 80.4–93.1%) received matched therapy in the first-line setting. Overall, 73% of patients initiated first-line treatment after NGS results became available, which was associated with a higher likelihood of matched therapy (OR 5.86; P<0.001) and longer TTD (6.3 vs 2.6 months; HR 0.59; P<0.001). Among patients with AGA, matched therapy was associated with significantly longer TTD (21.2 vs 3.5 months; HR 0.25; P < 0.001) and OS (45.4 vs 16.3 months; HR 0.44; P = 0.019) than non-targeted systemic therapy.Conclusion: Within a nationwide precision oncology program, matched therapy was delivered to nearly 90% of patients with AGA. Earlier NGS result availability improved delivery of precision oncology, whereas receipt of matched therapy was associated with improved overall survival.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501274
Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer With a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501274
Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer With a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion
- 10 March 2026
- Published by Elsevier in Lung Cancer
- Vol. 215, 109370
Increased detection of NRG1 fusions in non-squamous non–small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort
- 10 March 2026
- Published by Elsevier in Lung Cancer
- Vol. 215, 109370
Increased detection of NRG1 fusions in non-squamous non–small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort
- Open Access
- 17 January 2018
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 105 (2) , e192-e203
Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer
Background: Neoadjuvant chemoradiotherapy (CRT) is one of the preferred initial treatment strategies for locally advanced rectal cancer. Responses are variable, and most patients still require surgery. The aim of this study was to identify molecular mechanisms determining poor response to CRT. Methods: Global gene expression and pathway enrichment were assessed in pretreatment biopsies from patients with non-metastatic cT2–4 N0–2 rectal cancer within 7 cm of the anal verge. Downstream Akt activation was assessed in an independent set of pretreatment biopsies and in colorectal cancer cell lines using immunohistochemistry and western blot respectively. The radiosensitizing effects of the Akt inhibitor MK2206 were assessed using clonogenic assays and xenografts in immunodeficient mice. Results: A total of 350 differentially expressed genes were identified, of which 123 were upregulated and 199 downregulated in tumours from poor responders. Mitochondrial oxidative phosphorylation (P < 0·001) and phosphatidylinositol signalling pathways (P < 0·050) were identified as significantly enriched pathways among the set of differentially expressed genes. Deregulation of both pathways is known to result in Akt activation, and high immunoexpression of phosphorylated Akt S473 was observed among patients with a poor histological response (tumour regression grade 0–2) to CRT (75 per cent versus 48 per cent in those with a good or complete response; P = 0·016). Akt activation was also confirmed in the radioresistant cell line SW480, and a 50 per cent improvement in sensitivity to CRT was observed in vitro and in vivo when SW480 cells were exposed to the Akt inhibitor MK2206 in combination with radiation and 5-fluorouracil. Conclusion: Akt activation is a key event in the response to CRT. Pharmacological inhibition of Akt activation may enhance the effects of CRT. Surgical relevanceOrgan preservation is an attractive alternative in rectal cancer management following neoadjuvant chemoradiotherapy (CRT) to avoid the morbidity of radical surgery. Molecular steps associated with tumour response to CRT may provide a useful tool for the identification of patients who are candidates for no immediate surgery.In this study, tumours resistant to CRT were more likely to have activation of specific genetic pathways that result in phosphorylated Akt (pAkt) activation. Pretreatment biopsy tissues with high immunoexpression of pAkt were more likely to exhibit a poor histological response to CRT. In addition, the introduction of a pAkt inhibitor to cancer cell lines in vitro and in vivo led to a significant improvement in sensitivity to CRT.Identification of pAkt-activated tumours may thus allow the identification of poor responders to CRT. In addition, the concomitant use of pAkt inhibitors to increase sensitivity to CRT in patients with rectal cancer may constitute an interesting strategy for increasing the chance of a complete response to treatment and organ preservation.
- 17 January 2018
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 105 (2) , e192-e203
Open AccessEffect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer
Background: Neoadjuvant chemoradiotherapy (CRT) is one of the preferred initial treatment strategies for locally advanced rectal cancer. Responses are variable, and most patients still require surgery. The aim of this study was to identify molecular mechanisms determining poor response to CRT. Methods: Global gene expression and pathway enrichment were assessed in pretreatment biopsies from patients with non-metastatic cT2–4 N0–2 rectal cancer within 7 cm of the anal verge. Downstream Akt activation was assessed in an independent set of pretreatment biopsies and in colorectal cancer cell lines using immunohistochemistry and western blot respectively. The radiosensitizing effects of the Akt inhibitor MK2206 were assessed using clonogenic assays and xenografts in immunodeficient mice. Results: A total of 350 differentially expressed genes were identified, of which 123 were upregulated and 199 downregulated in tumours from poor responders. Mitochondrial oxidative phosphorylation (P < 0·001) and phosphatidylinositol signalling pathways (P < 0·050) were identified as significantly enriched pathways among the set of differentially expressed genes. Deregulation of both pathways is known to result in Akt activation, and high immunoexpression of phosphorylated Akt S473 was observed among patients with a poor histological response (tumour regression grade 0–2) to CRT (75 per cent versus 48 per cent in those with a good or complete response; P = 0·016). Akt activation was also confirmed in the radioresistant cell line SW480, and a 50 per cent improvement in sensitivity to CRT was observed in vitro and in vivo when SW480 cells were exposed to the Akt inhibitor MK2206 in combination with radiation and 5-fluorouracil. Conclusion: Akt activation is a key event in the response to CRT. Pharmacological inhibition of Akt activation may enhance the effects of CRT. Surgical relevanceOrgan preservation is an attractive alternative in rectal cancer management following neoadjuvant chemoradiotherapy (CRT) to avoid the morbidity of radical surgery. Molecular steps associated with tumour response to CRT may provide a useful tool for the identification of patients who are candidates for no immediate surgery.In this study, tumours resistant to CRT were more likely to have activation of specific genetic pathways that result in phosphorylated Akt (pAkt) activation. Pretreatment biopsy tissues with high immunoexpression of pAkt were more likely to exhibit a poor histological response to CRT. In addition, the introduction of a pAkt inhibitor to cancer cell lines in vitro and in vivo led to a significant improvement in sensitivity to CRT.Identification of pAkt-activated tumours may thus allow the identification of poor responders to CRT. In addition, the concomitant use of pAkt inhibitors to increase sensitivity to CRT in patients with rectal cancer may constitute an interesting strategy for increasing the chance of a complete response to treatment and organ preservation.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi140
Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi140
Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
- Open Access
- 11 December 2014
- Published by Springer Nature in BMC Medical Genomics
- Vol. 7 (1) , 68
Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to identify biomarkers capable of predicting complete response to nCRT. We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT. Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT. We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene, whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients. This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery.
- 11 December 2014
- Published by Springer Nature in BMC Medical Genomics
- Vol. 7 (1) , 68
Open AccessOverexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients
Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to identify biomarkers capable of predicting complete response to nCRT. We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT. Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT. We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene, whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients. This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery.